Last reviewed · How we verify
ziziphus honey
ziziphus honey is a Small molecule drug developed by Postgraduate Medical Institute, Lahore. It is currently in Phase 3 development for Gastrointestinal disorders, Stress-related disorders. Also known as: sidr honey, honey.
Ziziphus honey has been traditionally used to treat various gastrointestinal issues and stress-related disorders.
Ziziphus honey has been studied in clinical trials for its potential healing effects on wounds and possibly idiopathic dilated cardiomyopathy. However, the exact mechanism of action of ziziphus honey is currently unknown.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ziziphus honey |
|---|---|
| Also known as | sidr honey, honey |
| Sponsor | Postgraduate Medical Institute, Lahore |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal, Neurology |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action of ziziphus honey is not well understood, but it is believed to have anti-inflammatory and antioxidant properties, which may contribute to its therapeutic effects. Additionally, ziziphus honey may interact with the gut-brain axis to produce its anxiolytic and anti-ulcerative effects.
Approved indications
- Gastrointestinal disorders, Stress-related disorders
Common side effects
- Gastrointestinal upset
- Allergic reactions
Key clinical trials
- Healing Effect of Ziziphus Honey on Extracted Tooth Socket in Humans by Evaluating the Levels of BMP-2 and OPN (PHASE3)
- Honey in Idiopathic Dilated Cardiomyopathy (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ziziphus honey CI brief — competitive landscape report
- ziziphus honey updates RSS · CI watch RSS
- Postgraduate Medical Institute, Lahore portfolio CI
Frequently asked questions about ziziphus honey
What is ziziphus honey?
How does ziziphus honey work?
What is ziziphus honey used for?
Who makes ziziphus honey?
Is ziziphus honey also known as anything else?
What development phase is ziziphus honey in?
What are the side effects of ziziphus honey?
Related
- Manufacturer: Postgraduate Medical Institute, Lahore — full pipeline
- Therapeutic area: All drugs in Gastrointestinal, Neurology
- Indication: Drugs for Gastrointestinal disorders, Stress-related disorders
- Also known as: sidr honey, honey
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing